Burn Wound
Conditions
Keywords
immunonutrition
Brief summary
This pilot study aims to assess the feasibility of providing immunonutrition supplementation to older burn patients (age 55 and older) and its impact on burn wound healing. Supplements containing arginine and omega 3 fatty acids have been shown to have beneficial effects on healing in other types of wounds but data within the burn population remains limited. 20 participants will be randomized into two arms, immunonutrition or conventional supplement and can expect to be on study for 3 months.
Detailed description
Studies performed previously in burn patients have had mixed patient cohorts with small sample sizes and these have failed to show any large improvements in wound healing. However, in older populations the investigators suspect that immunonutrition supplements may have a larger benefit to these patients as they often present with malnutrition and are more likely to struggle with delayed wound healing. In this pilot study, the investigators look to assess the impact of immunonutrition supplements the burn wound healing of adults over the age of 55 years with 1-15% total burn surface area (TBSA) partial thickness and full thickness burn injuries. The primary outcome objective of the study will be time to complete wound closure. The secondary objectives include need for surgical grafting, length of inpatient stay, and infections including pneumonia, urinary tract infections, wound infections, and blood stream infections.
Interventions
DIETARY_SUPPLEMENTImpact Advanced Recovery
L-arginine and omega-3 rich supplement
DIETARY_SUPPLEMENTBoost High Protein
conventional supplement
Sponsors
University of Wisconsin, Madison
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject has partial of full thickness thermal injury of 1-15% of total body surface area (TBSA) * Subject has an inpatient admission for their burn * Subject or authorized decision maker understands the study procedures and can provide informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator
Exclusion criteria
* Subject with inhalation injury and/or intubation * Subject receiving immunosuppressive medications including chronic steroids, immune modulating medications, and chemotherapy prior to admission * Subject with pre-existing severe chronic liver disease or end stage renal disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to Complete Wound Closure | up to 3 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Surgical Grafting | up to 3 months | — |
| Length of Inpatient Stay | up to 3 months | — |
| Incidence of Infections | up to 3 months | Infectious complications include pneumonia, urinary tract infection, wound infection, and blood stream infection. |
Countries
United States
Outcome results
None listed